CERVOMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.94 USD | -3.81% |
|
+1.34% | +148.23% |
| 29/05 | JonesTrading Starts CervoMed With Buy Rating, $70 Price Target | MT |
| 20/05 | CervoMed Names William Elder CFO | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 43.3 | 156.3 | - | - |
| Enterprise Value (EV) 1 | 43.3 | 111 | 43.43 | 92.83 |
| P/E ratio | -9.3 x | -11.9 x | -8.76 x | -6.52 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 6.06 x | 17.7 x | 26.8 x | - |
| EV / Revenue | 6.06 x | 12.6 x | 7.44 x | - |
| EV / EBITDA | -5.54 x | -7.55 x | -1.18 x | -1.72 x |
| EV / FCF | - | -8.54 x | -1.46 x | -2.16 x |
| FCF Yield | - | -11.7% | -68.3% | -46.3% |
| Price to Book | - | 3.85 x | 2.22 x | 3.89 x |
| Nbr of stocks (in thousands) | 5,675 | 8,254 | - | - |
| Reference price 2 | 7.630 | 18.94 | 18.94 | 18.94 |
| Announcement Date | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 7.145 | 8.833 | 5.833 | - |
| EBITDA 1 | - | -7.813 | -14.7 | -36.9 | -54 |
| EBIT 1 | - | -7.813 | -12.9 | -26.77 | -38.8 |
| Operating Margin | - | -109.35% | -146.04% | -458.86% | - |
| Earnings before Tax (EBT) 1 | - | -2.172 | -14.1 | -32.45 | -45.8 |
| Net income 1 | -5.803 | -2.172 | -14.1 | -32.45 | -45.8 |
| Net margin | - | -30.4% | -159.62% | -556.29% | - |
| EPS 2 | -1.290 | -0.8200 | -1.587 | -2.163 | -2.907 |
| Free Cash Flow 1 | - | - | -13 | -29.65 | -42.95 |
| FCF margin | - | - | -147.17% | -508.29% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 13/07/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.526 | 2.491 | 2.347 | 2.1 | 2.1 | 2.1 |
| EBITDA 1 | - | -2.48 | -2.595 | -3.4 | -4.4 | -4.9 |
| EBIT 1 | -2.675 | -2.48 | -2.595 | -2.9 | -3.45 | -3.95 |
| Operating Margin | -175.25% | -99.59% | -110.55% | -138.1% | -164.29% | -188.1% |
| Earnings before Tax (EBT) 1 | 2.15 | -2.362 | -2.514 | -3.1 | -3.9 | -4.6 |
| Net income 1 | 2.15 | -2.362 | -2.514 | -3.1 | -3.9 | -4.6 |
| Net margin | 140.87% | -94.85% | -107.12% | -147.62% | -185.71% | -219.05% |
| EPS 2 | 0.6500 | -0.9500 | -0.4100 | -0.3367 | -0.4133 | -0.4600 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 13/11/23 | 29/03/24 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 45.3 | 113 | 63.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -13 | -29.7 | -43 |
| ROE (net income / shareholders' equity) | - | - | -56.4% | -46.9% | -60.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.920 | 8.530 | 4.870 |
| Cash Flow per Share 2 | - | - | -1.680 | -2.470 | -3.530 |
| Capex 1 | - | - | 1 | 2 | 2 |
| Capex / Sales | - | - | 11.32% | 34.29% | - |
| Announcement Date | 13/07/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
18.94
USD
Average target price
55
USD
Spread / Average Target
+190.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +148.23% | 156M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- CRVO Stock
- Financials CervoMed Inc.
